本文選題：慢性阻塞性肺疾病 + 茚達(dá)特羅��； 參考：《實(shí)用醫(yī)學(xué)雜志》2014年11期

【摘要】：目的:觀察并分析茚達(dá)特羅在極重度通氣功能障礙慢性阻塞性肺疾病(COPD)患者中的臨床應(yīng)用效果及安全性。方法:對處于穩(wěn)定期,沙美特羅氟替卡松聯(lián)合噻托溴銨吸入后仍然感覺呼吸困難的極重度通氣功能障礙COPD患者,以茚達(dá)特羅替代沙美特羅氟替卡松,觀察患者用藥前和用藥90 d后的肺功能指標(biāo)、COPD評估測試(CAT)評分的變化。結(jié)果:患者用藥90 d后用力肺活量(FVC)平均增加0.15 L,深吸氣量(IC)平均增加0.51 L,均有較大的改善;FEV1與FEV1/FVC%變化不大;全部患者CAT評分比用藥前平均下降8.7分,客觀表現(xiàn)為呼吸困難的緩解和對生活質(zhì)量影響程度降低,而且無合并癥加重。結(jié)論:茚達(dá)特羅可以改善極重度通氣功能障礙COPD患者的肺功能,改善患者呼吸困難狀況,提高生活質(zhì)量且有一定的安全性。
[Abstract]:Objective: to observe and analyze the clinical efficacy and safety of indendibuterol in patients with extremely severe ventilation dysfunction chronic obstructive pulmonary disease (COPDD). Methods: in patients with extremely severe ventilatory dysfunction (COPD) who were still feeling dyspnea after inhalation of salmeterol fluticasone combined with tiotropium, the patients with severe ventilatory dysfunction were treated with indoletriol instead of salmeterol fluticasone. Before and 90 days after treatment, the pulmonary function index and the score of COPD evaluation test (CAT) were observed. Results: after 90 days of treatment, forced vital capacity (FVC) and inspiratory volume (ICI) were increased by 0.15 L and 0.51 L, respectively. FEV1 and FEV1 / FVC% were significantly improved, and the CAT scores of all patients were decreased by 8.7 points compared with those before medication. The objective manifestation is the relief of dyspnea and the decrease of quality of life. Conclusion: indolebuterol can improve lung function of patients with extremely severe ventilation dysfunction (COPD), improve breathing condition, improve quality of life and have certain safety.
【作者單位】： 呼吸疾病國家重點(diǎn)實(shí)驗(yàn)室 國家呼吸疾病臨床研究中心 廣州醫(yī)科大學(xué)附屬第一醫(yī)院 廣州呼吸疾病研究所;
【分類號】：R563.9
，

本文編號：1803959